Induced Pluripotent Stem Cells
GMP iPSC reprogramming, gene editing and differentiation
Leading Industry Experts
With experience generating and characterizing over 200 induced pluripotent stem cell (iPSC) lines, OmniaBio can deliver high-quality iPSCs that meet the unique requirements of each client. Our team of iPSC industry leaders take a personalized approach to each project and can help you at every step.
iPSC Offerings
- Good Manufacturing Practices (GMP)-compliant reprogramming platforms to produce therapeutic-grade iPSC lines
- Expertise using a variety of different nucleases and delivery methods, including CRISPR-Cas9, to generate gene-edited iPSC lines with knock-in, knock-out, and single nucleotide polymorphism (SNP) modifications
- An optimized screening approach for fast and accurate identification of single-cell clones of interest
- Process scale-up for the generation of a variety of differentiated cell types
- An in-house analytics platform to enable cell line characterization
Services for Your Project Phase
Process
Development
Experts in optimization to ensure reliable scale-up to produce cell and gene therapies.
GMP
Manufacturing
Our state-of-the-art facility is equipped with the tools and flexibility to manufacture your product at a commercial scale.
Analytical
Development
Providing a robust suite of analytical capabilities that are integrated through your product’s lifecycle to support the development process.
Regulatory
Support
With in-depth knowledge, we can guide you through the regulatory landscape to approval.
Our Expertise on Demand
Related Thought Leadership & Resources
CCRM Australia, with its Canadian partners OmniaBio Inc. and Toronto-based CCRM, has signed a Letter of Intent with The University of Queensland to establish the Advanced Cell Therapy Manufacturing Initiative (ACTMI)...
The Canadian Advanced Therapies Training Institute (CATTI) Inc. has launched its first in-person training site at the University of Guelph...
Catamaran Bio Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio Inc., a CDMO focused on...